Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 9,935 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: Impulsive Behavior, Mental Disorders
Interventions: Cognitive Control Training; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education; Drug · Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 12 Years to 25 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more

Conditions: Diabetic Macular Edema
Interventions: Alflibercept; Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Ulcerative Colitis (UC)
Interventions: ONO-6414, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neoplasms
Interventions: Self-affirmation writing; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Little Rock, Arkansas • North Little Rock, Arkansas

Conditions: Meningitis, Meningococcal, Serogroup B
Interventions: rLP2086; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Proliferative Diabetic Retinopathy
Interventions: Brolucizumab 6 mg, Panretinal photocoagulation laser; Biological · Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 40
States / cities: Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more

Conditions: Hearing Loss, Sensorineural
Interventions: hearing aids; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Mantle Cell Lymphoma
Interventions: P276-00; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 13
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota + 9 more

Conditions: Colorectal Cancer Screening
Interventions: FLU-FIT Program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 75 Years
Enrollment: 7,465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Oakland, California

Conditions: Intraocular Pressure
Interventions: Alphagan, Phenylephrine, Tropicamide; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
Interventions: Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing); Biological
Lead sponsor: Sarang K. Yoon, DO, MOH; Other
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: BJ-001, Pembrolizumab; Drug
Lead sponsor: BJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more

Conditions: Community-acquired Infection
Interventions: GSK2251052; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cognition Disorder, Stroke, Occlusion Carotid
Interventions: Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy); Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: Youth Incarceration, Health Care Utilization
Interventions: Whole Person Care (WPC) Reentry Program - Pre & Post Release services; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 24 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV-1-infection
Interventions: Bictegravir/emtricitabine/tenofovir alafenamide; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Gingival Recession
Interventions: Gum Graft Placed on Denuded Bone, Gum Graft Placed on Split Thickness Periosteal Bed Preparation; Procedure
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 95 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Vinorelbine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 22
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more

Conditions: Thrombosis
Interventions: SoftSeal Hemostatic Pad; Device
Lead sponsor: HealthEast Care System; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Mantle Cell Lymphoma
Interventions: Panobinostat, Bortezomib; Drug
Lead sponsor: Anand Jillella; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Prostate Cancer
Interventions: Staple Ligation, Selective Suture Ligation, Single Suture Ligation; Procedure
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Solid Tumors, Lymphoma
Interventions: Ulevostinag, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Santa Monica, California + 5 more

Search by objective public record fields.

Cognitive Control Training for Urgency in a Naturalistic Clinical Setting

Early Detection and Intervention for the Prevention of Psychosis

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis

Self-affirmation Intervention for People Newly Diagnosed With Advanced Cancer

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Self-efficacy-based Auditory Rehabilitation With Over-the-Counter Hearing Aids

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

FLU-FIT Program at Kaiser Permanente Northern California

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors

An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects

NeuroCognition After Carotid Recanalization

A Pilot Trial of a Network Intervention for Youth After Incarceration

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

Dimensional Changes: Randomized Clinical Trial

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

Heart and Hands Study II: A Retrospective Data Collection & Analysis Project

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Staple vs. Suture in Robotic Prostatectomy

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)